{
  "cik": 1750149,
  "cik_padded": "0001750149",
  "entityName": "Inhibikase Therapeutics, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-126371",
      "filed": "2026-03-26",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 13399.0,
        "cash": 178800000.0,
        "eps_diluted": -0.49,
        "free_cash_flow": -27799863.0,
        "net_income": -48259189.0,
        "operating_cash_flow": -27786464.0,
        "operating_income": -51974283.0,
        "stockholders_equity": 172903679.0,
        "total_assets": 181204516.0,
        "total_liabilities": 8300837.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.04800844636741362,
        "roa_avg2y": -0.34494951154478426,
        "roa_period_end": -0.2663244275876656,
        "roe_avg2y": -0.36045260028590437,
        "roe_period_end": -0.27911024958584024
      }
    },
    {
      "accn": "0001193125-26-126371",
      "filed": "2026-03-26",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 0.0,
        "cash": 97500000.0,
        "eps_diluted": -1.16,
        "free_cash_flow": -19148067.0,
        "net_income": -27519886.0,
        "operating_cash_flow": -19148067.0,
        "operating_income": -28589068.0,
        "stockholders_equity": 94866280.0,
        "total_assets": 98599846.0,
        "total_liabilities": 3733566.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.039356091542748384,
        "roa_avg2y": -0.4866190307925116,
        "roa_period_end": -0.279106784811814,
        "roe_avg2y": -0.5200074350789663,
        "roe_period_end": -0.29009133698506995
      }
    },
    {
      "accn": "0001193125-26-126371",
      "filed": "2026-03-26",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 14238.0,
        "cash": 9200000.0,
        "eps_diluted": -3.16,
        "free_cash_flow": -18099281.0,
        "net_income": -19028883.0,
        "operating_cash_flow": -18085043.0,
        "operating_income": -20089792.0,
        "stockholders_equity": 10977922.0,
        "total_assets": 14506647.0,
        "total_liabilities": 3528725.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.32143833778378095,
        "roa_avg2y": -0.9648814753787142,
        "roa_period_end": -1.3117354410016318,
        "roe_avg2y": -1.188810233789226,
        "roe_period_end": -1.7333775007692713
      }
    },
    {
      "accn": "0000950170-25-046096",
      "filed": "2025-03-27",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 243255.0,
        "cash": 7190000.0,
        "eps_diluted": -4.28,
        "free_cash_flow": -17594358.0,
        "net_income": -18054155.0,
        "operating_cash_flow": -17351103.0,
        "operating_income": -18128608.0,
        "stockholders_equity": 21035401.0,
        "total_assets": 24936297.0,
        "total_liabilities": 3900896.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.18544433738154076,
        "roa_avg2y": -0.5356815630397492,
        "roa_period_end": -0.7240110670802485,
        "roe_avg2y": -0.6073630446611871,
        "roe_period_end": -0.8582748196718475
      }
    },
    {
      "accn": "0000950170-24-037160",
      "filed": "2024-03-27",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 0.0,
        "cash": 40750000.0,
        "eps_diluted": -0.81,
        "free_cash_flow": -14297051.0,
        "net_income": -14786063.0,
        "operating_cash_flow": -14297051.0,
        "operating_income": -14766140.0,
        "stockholders_equity": 38415549.0,
        "total_assets": 42469999.0,
        "total_liabilities": 4054450.0
      },
      "period_end": "2021-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.1055418991929544,
        "roa_avg2y": -0.5165192806173962,
        "roa_period_end": -0.34815312804693027,
        "roe_avg2y": -0.6135307943034327,
        "roe_period_end": -0.3848978703909711
      }
    },
    {
      "accn": "0000950170-23-011133",
      "filed": "2023-03-31",
      "fiscal_year": 2020,
      "form": "10-K",
      "fundamental_units": {
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "net_income": -2847894.0,
        "operating_cash_flow": -1129355.0,
        "operating_income": -2818492.0,
        "stockholders_equity": 9784356.0,
        "total_assets": 14782706.0,
        "total_liabilities": 4998350.0
      },
      "period_end": "2020-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.510851199608845,
        "roa_period_end": -0.19265038484834915,
        "roe_avg2y": -1.0758258819796236,
        "roe_period_end": -0.29106606505323396
      }
    },
    {
      "accn": "0000950170-22-005203",
      "filed": "2022-03-31",
      "fiscal_year": 2019,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -4490016.0
      },
      "period_end": "2019-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-126371",
    "filed": "2026-03-26",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2836",
  "sic_description": "Biological Products, (No Diagnostic Substances)",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001750149.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001750149.json"
  },
  "ticker": "IKT"
}